Adenosine receptors as emerging therapeutic targets for diabetic kidney disease
- Author:
Eun Seon PAK
1
;
Jin Joo CHA
;
Dae Ryong CHA
;
Keizo KANASAKI
;
Hunjoo HA
Author Information
- Publication Type:Review Article
- From:Kidney Research and Clinical Practice 2022;41(Suppl 2):S74-S88
- CountryRepublic of Korea
- Language:English
- Abstract: Diabetic kidney disease (DKD) is now a pandemic worldwide, and novel therapeutic options are urgently required. Adenosine, an adenosine triphosphate metabolite, plays a role in kidney homeostasis through interacting with four types of adenosine receptors (ARs): A1AR, A2AAR, A2BAR, and A3AR. Increasing evidence highlights the role of adenosine and ARs in the development and progression of DKD: 1) increased adenosine in the plasma and urine of diabetics with kidney injury, 2) increased expression of each of the ARs in diabetic kidneys, 3) the protective effect of coffee, a commonly ingested nonselective AR antagonist, on DKD, and 4) the protective effect of AR modulators in experimental DKD models. We propose AR modulators as a new therapeutic option to treat DKD. Detailed mechanistic studies on the pharmacology of AR modulators will help us to develop effective first-in-class AR modulators against DKD.
